# BMS-986012 in Relapsed/Refractory SCLC

> **NCT02247349** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 106 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** BMS-986012 (anti-fucosyl-GM1)
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02247349
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-14
- **Primary completion:** 2022-12-21
- **Final completion:** 2022-12-22
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2024-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02247349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02247349, "BMS-986012 in Relapsed/Refractory SCLC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02247349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*